Clinical trial
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
NCT00002662 · Aventis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00002662 |
|---|---|
| Title | Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer |
| Official title | PHASE III COMPARISON OF TAXOTERE (DOCETAXEL) AND TAXOL (PACLITAXEL) IN PATIENTS WITH ADVANCED BREAST CANCER |
| Lead sponsor | Aventis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, paclitaxel |
| Start date | Aug 1, 1994 |
| Completion | Jun 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 2, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: